Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outset Medical (OM) Raw Materials (2019 - 2025)

Outset Medical (OM) has disclosed Raw Materials for 7 consecutive years, with $27.2 million as the latest value for Q4 2025.

  • Quarterly Raw Materials rose 5.76% to $27.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $27.2 million through Dec 2025, up 5.76% year-over-year, with the annual reading at $27.2 million for FY2025, 5.76% up from the prior year.
  • Raw Materials for Q4 2025 was $27.2 million at Outset Medical, up from $26.0 million in the prior quarter.
  • The five-year high for Raw Materials was $27.2 million in Q4 2025, with the low at $10.9 million in Q1 2021.
  • Average Raw Materials over 5 years is $20.9 million, with a median of $20.8 million recorded in 2022.
  • The sharpest move saw Raw Materials surged 150.93% in 2021, then dropped 9.3% in 2023.
  • Over 5 years, Raw Materials stood at $18.1 million in 2021, then increased by 13.85% to $20.6 million in 2022, then dropped by 9.3% to $18.7 million in 2023, then skyrocketed by 37.41% to $25.7 million in 2024, then increased by 5.76% to $27.2 million in 2025.
  • According to Business Quant data, Raw Materials over the past three periods came in at $27.2 million, $26.0 million, and $26.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.